Cancer Guidelines Database

This is a clinical practice guideline for women who are at average risk for developing cervical cancer. The guideline examines cervical cancer screening in these patients, including screening techniques, when to instigate screening, and intervals for screening. Recommendations are provided based on age, such as whether patients are under 25 years of age, 25-65 years of age, or over 65 years of age.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the curative management of these patients with radiotherapy, including its indications, techniques and outcomes. Other therapies that modify the efficacy of radiotherapy when used concurrently or in sequence, such as chemotherapy or surgery, are also discussed.

This is a clinical practice guideline for patients with suspected or confirmed adenocarcinoma in situ (AIS) of the uterine cervix. Recommendations are provided for the diagnosis, treatment, and follow-up of these patients. The guideline discusses excisional treatment under colposcopic guidance, treatment for women who desire to preserve fertility, hysterectomy, and more.

This is a clinical practice guideline for patients with cancer of the uterine cervix, including those with squamous cell carcinomas, adenocarcinomas and adenosquamous carcinomas. The guideline examines screening, diagnosis, staging, treatment, and follow-up of these patients. Specific topics discussed include investigations of abnormal pap smears, investigations for staging, estrogen replacement therapy, and much more. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline on cervical cancer screening. This guideline provides recommendations regarding screening intervals, the appropriate management of screen-detected abnormalities, screening in specific populations and abnormal vaginal bleeding. Outcomes of interest include cervical cancer mortality, cervical cancer diagnosis and precancerous high grade lesion detection. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of August 30th, 2019.

This is a clinical practice guideline for women who have been diagnosed with uterine cervical cancer. The guideline discusses the treatment of these patients, and recommendations are separated based on disease type/stage. Specific topics examined include the primary treatment for cervical precancerous lesions and IA cervical cancer, the primary treatment for stage IB-II cervical cancer, postoperative therapy for stage IB–II cervical cancer, the primary therapy for stage III-IV cervical cancer, therapies for relapsed cervical cancer, and the management of cervical cancer during pregnancy.

This is a clinical practice guideline for asymptomatic women with suspected or confirmed adnexal masses. The guideline provides recommendations on various imaging procedures used to confirm the presence of adnexal masses, and to determine whether they are benign or malignant. The appropriateness of procedures indicated in specific clinical scenarios (measured by validity, reliability/reproducibility, clinical applicability, relative radiation levels, etc.) is examined. Recommendations are separated based on menopausal status.

This is a clinical practice guideline for women with cervical intraepithelial neoplasia (CIN). Recommendations are provided on the use of thermal ablation for the treatment of these women, with the ultimate goal of reducing the incidence of cervical cancer. The guideline compares thermal ablation to other treatment approaches such as cryotherapy, large loop excision of the transformation zone (LLETZ), and cold knife conization (CKC). Different modalities of thermal ablation (e.g., those that differ by temperature, number of applications, duration, etc.) are also discussed.

This is a clinical practice guideline on the screening for cervical cancer. The guideline examines the age at which to begin and end screening, the optimal interval for screening, the effectiveness of different screening strategies, and related benefits and harms of different screening strategies. Specific strategies discussed include screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years, screening every 3 years with cervical cytology alone, screening every 5 years with high-risk human papillomavirus (HPV) testing alone, and screening every 5 years with high-risk HPV testing in combination with cytology (co-testing) in women aged 30 to 65 years.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline for patients with cervical cancer. The guideline examines the staging, management, and follow-up of these patients. Specific management recommendations are made for stage T1a, T1b1/T2a1 cancer, clinically occult cervical cancer diagnosed after simple hysterectomy, early and locally advanced cervical cancer (LACC), primary distant metastatic disease, cervical cancer in pregnancy (CCIP), and recurrent disease. The use of fertility sparing treatment (FST) is also discussed.

This is a clinical practice guideline for adult oncology patients with neutropenia. The guideline examines the appropriate prescribing of filgrastim for these patients. Indications for which filgrastim should be used are discussed by disease site group. Disease site groups considered include breast, central nervous system, gastrointestinal, gynecologic, genitourinary, hematologic, and thoracic, amongst others.

This is a clinical practice guideline on the use of the 9-valent human papillomavirus (HPV) vaccine. The guideline examines the effect and safety of the 9-valent HPV vaccines, the recommended age for a 3-dose schedule, the vaccine's efficacy among middle-aged women, and the efficacy of a 2-dose schedule.

This is a clinical practice guideline for women with potentially curable, non-operable, locally advanced cervical cancer. The guideline provides recommendations on treatment using brachytherapy (BT), and compares different forms of BT such as two-dimensional BT, computed tomography-guided BT, magnetic resonance (MR)-guided intracavitary BT, and MR-guided intracavitary/interstitial BT. Outcomes of interest include survival, local tumour control, and toxicity.

This is a clinical practice guideline for patients with cervical cancer. The guideline discusses the diagnosis, treatment, and surveillance of patients with primary cervical cancer, and also provides recommendations regarding the treatment of recurrent cervical cancer. Specific diagnostic techniques examined include computed tomography (CT) and positron emission tomography (PET) scans, while treatment modalities examined include laparoscopic and robotic radical hysterectomy, nerve sparing radical hysterectomy, intensity-modulated radiation therapy (IMRT), and more.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline for the vaccination of human papillomavirus (HPV) for the prevention of cervical cancer in women. The guideline examines the efficacy of 2-dose schedule vaccination, the efficacy of 3-dose schedule vaccination in middle-aged women, the ideal age of 3-dose schedule vaccination, the safety of HPV preventive vaccine, and the cross-protective ability of each HPV preventive vaccine.

This is a clinical practice guideline for the use of myeloid growth factors in adult patients with solid tumours and non-myeloid malignancies. Benefits and risks are reviewed, the role of biosimilars is discussed, and recommendations are provided for prophylactic and therapeutic uses of both granulocyte and granulocyte-macrophage colony stimulating factors (CSFs). Recommendations are also given regarding the use of CSFs in the hematopoietic cell transplant setting. Outcomes of interest include efficacy of CSFs, mortality, length of hospitalization, toxicity, and adverse effects.

This is a clinical practice guideline for females and males between the ages of 9 and 26. The guideline examines the use of the human papillomavirus (HPV) vaccination for the purposes of cancer prevention. The ages at which routine vaccination and catch-up vaccination should occur are discussed, as well as which vaccines should be used for males and females. Special populations such as men who have sex with other men and immunocompromised persons are also addressed.

This is a clinical practice guideline for palliative oncology patients 18 years of age or older with low grade/ low volume/ malignancy-associated urogenital or gastrointestinal bleeding, or with malignant gastrointestinal obstruction, compression or invasion. External beam radiotherapy (EBRT) with or without , brachytherapy, stent placement, and surgical bypass are discussed as therapeutic options. Outcomes of interest include clinical improvement of symptoms, quality of life, and survival.

This is a clinical practice guideline for women who are at risk of developing cervical cancer. The guideline examines the optimal methods for cervical cancer screening and the management of women with abnormal screening results. Primary screening, exiting screening, triage and post-triage time periods, and the treatment of women with precursor lesions are all discussed. Different recommendations are provided based on economic resource level (i.e., basic, limited, enhanced or maximal).

This is a clinical practice guideline for women diagnosed with invasive cervical cancer. The guideline examines the most effective antitumour and palliative care interventions for clinicians and planners. Treatment options that are discussed include cone biopsy, extrafascial hysterectomy, modified radical or radical hysterectomy, and combinations of surgery, chemotherapy, and radiation therapy.

This is a clinical practice guideline for patients with cervical cancer including squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. The guideline discusses diagnosis and workup, principles of staging and surgery, primary treatment, adjuvant treatment, surveillance, and therapy for relapse. Special topics of consideration include incidental cervical cancer, radiation therapy, and cervical cancer and pregnancy.

This guideline outlines the screening, diagnosis, treatment, and follow-up of human papillomavirus related cancers. The guideline examines appropriate vaccination strategies, screening (including care controversies), and treatment including chemotherapy and surgical options. Outcomes of interest include fertility sparing and reduction of unnecessary Pap testing. Provincial resources are provided.

This is a clinical practice guideline for the screening and treatment of precancerous lesions for cervical cancer prevention. The guideline focuses specifically on the screening for cervical intraepithelial neoplasia 2 & 3 and the treatment of those lesions to prevent cervical cancer in women who tested positive after screening. In formulating the recommendations, the guideline authors specifically took into account resource implications in the Saudi context.

This clinical practice guideline examines the impact of fertility drugs on the risk of cancer in women. The guideline looks at the association between use of fertility drugs and increased risk of developing invasive ovarian, breast, endometrial, colon and thyroid cancers as well as non-Hodgkin lymphoma and malignant melanoma. The association between fertility drugs and borderline ovarian tumours is also examined.